This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) has been developed to provide clinicians with a practical guide that considers the whole patient, their spectrum of risks and complications, and evidence-based approaches to treatment. It recommends that the choice of diabetes therapies must be individualized based on attributes specific to both patients and the medications themselves. Medication attributes that affect this choice include antihyperglycemic efficacy, mechanism of action, risk of inducing hypoglycemia, risk of weight gain, other adverse effects, tolerability, ease of use, likely adherence, cost, and safety in heart, kidney, or liver disease.
For patients with recent-onset T2D or mild hyperglycemia (A1C <7.5%), lifestyle therapy plus antihyperglycemic monotherapy (preferably with metformin) is recommended. Secondline medication all put…
